Aura Biosciences, Inc. (AURA)
$9.25
Live
Insights on Aura Biosciences, Inc.
Vs NVO
In the last 1 year, Novo Nordisk A/s has given 288.9% return, outperforming this stock by 326.7%
Performance
- $9.25$9.67$9.25
0.0%
Downside
Day's Volatility :4.32%
Upside
4.32%
- $8.13$19.18$9.25
12.11%
Downside
52 Weeks Volatility :57.61%
Upside
51.77%
Returns
| Period | Aura Biosciences, Inc. | Sector (Health Care) | Index (Russel 2000) |
|---|---|---|---|
3 Months | -20.19% | -1.4% | 0.0% |
6 Months | 3.93% | 2.2% | 2.0% |
1 Year | -36.82% | 6.0% | 5.3% |
3 Years | -37.5% | 26.3% | 19.9% |
Highlights
Market Capitalization | 398.8M |
Book Value | $4.37 |
Dividend Share | 0.0 |
Dividend Yield | 0.0% |
Earnings Per Share (EPS) | -1.98 |
Wall Street Target Price | 27.4 |
Profit Margin | 0.0% |
Operating Margin TTM | 0.0% |
Return On Assets TTM | -27.99% |
Return On Equity TTM | -46.17% |
Revenue TTM | 0.0 |
Revenue Per Share TTM | 0.0 |
Quarterly Revenue Growth YOY | 0.0% |
Gross Profit TTM | 0.0 |
EBITDA | -72.1M |
Diluted Eps TTM | -1.98 |
Quarterly Earnings Growth YOY | 0.0 |
EPS Estimate Current Year | -2.01 |
EPS Estimate Next Year | -2.38 |
EPS Estimate Current Quarter | -0.49 |
EPS Estimate Next Quarter | -0.51 |
Analyst Recommendation
- Current
- 1M Ago
- 3M Ago
Analyst Forecast
What analysts predicted
Upside of 196.22%
Peers
| Company Name | 1 Month | 6 Month | 1 Year | 3 Years | 5 Years |
|---|---|---|---|---|---|
 Aura Biosciences, Inc. | -9.93% | 3.93% | -36.82% | -37.5% | -37.5% |
 Moderna, Inc. | -10.67% | -32.6% | -16.46% | 43.93% | 437.58% |
 Regeneron Pharmaceuticals, Inc. | -0.66% | 0.54% | 20.22% | 43.69% | 111.47% |
 Novo Nordisk A/s | 2.15% | 146.19% | 299.73% | 451.49% | 690.33% |
 Seagen, Inc. | 6.95% | 7.06% | 57.98% | 15.54% | 167.56% |
 Vertex Pharmaceuticals Incorporated | -0.15% | 13.31% | 26.28% | 30.33% | 91.37% |
| Company Name | P/E Ratio | P/B Ratio | PEG Ratio | EPS | ROE | ROA | Div Yield | BVPS |
|---|---|---|---|---|---|---|---|---|
Aura Biosciences, Inc. | NA | NA | NA | -2.01 | -0.46 | -0.28 | 0.0 | 4.37 |
Moderna, Inc. | 34.92 | 34.92 | 0.0 | -3.42 | 0.07 | 0.01 | 0.0 | 44.49 |
Regeneron Pharmaceuticals, Inc. | 21.9 | 21.9 | 9.01 | 41.82 | 0.19 | 0.1 | 0.0 | 225.94 |
Novo Nordisk A/s | 42.86 | 42.86 | 2.03 | 1.66 | 0.82 | 0.22 | 0.01 | 2.52 |
Seagen, Inc. | NA | NA | 18.53 | -3.52 | -0.26 | -0.13 | 0.0 | 13.96 |
Vertex Pharmaceuticals Incorporated | 27.48 | 27.48 | 0.41 | 14.71 | 0.25 | 0.16 | 0.0 | 60.01 |
| Company Name | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin |
|---|---|---|---|---|---|
Aura Biosciences, Inc. | Buy | $398.8M | -37.5% | NA | 0.0% |
Moderna, Inc. | Buy | $38.1B | 437.58% | 34.92 | 11.33% |
Regeneron Pharmaceuticals, Inc. | Buy | $89.4B | 111.47% | 21.9 | 33.93% |
Novo Nordisk A/s | Buy | $409.3B | 690.33% | 42.86 | 33.4% |
Seagen, Inc. | Hold | $38.7B | 167.56% | NA | -33.55% |
Vertex Pharmaceuticals Incorporated | Buy | $90.2B | 91.37% | 27.48 | 35.4% |
Institutional Holdings
Matrix Capital Management Company, LLC
14.04%Medicxi Ventures Management (Jersey) Ltd
7.96%Eventide Asset Management, LLC
7.69%Adage Capital Partners Gp LLC
7.09%Citadel Advisors Llc
6.44%BlackRock Inc
4.90%
Corporate Announcements
Aura Biosciences, Inc. Earnings
Aura Biosciences, Inc.’s price-to-earnings ratio stands at None
Read More
Company Information
at aura biosciences, we are developing a new class of therapies to target and destroy cancer cells selectively, while leaving surrounding tissue unharmed – an approach we call molecular surgery. by safely eliminating cancer locally, we can treat early and transform the lives of people with a wide range of cancers that are poorly managed today. our lead program in ocular melanoma (om), also known as choroidal or uveal melanoma, is designed to remove cancer cells in the back of the eye as a first-line therapy, while allowing for the potential of preserving patients’ vision. the goal is to treat small ocular melanomas potentially long before the disease progresses and metastasizes to the liver, where it almost always is fatal. development of a first-in-class, non-radioactive treatment option to selectively destroy cancer cells would create the possibility to transform the treatment of this and other cancers where the disease can be detected early. by enabling physicians to treat cancer mo
Organization | Aura Biosciences, Inc. |
Employees | 70 |
CEO | Dr. Elisabet de los Pinos Ph.D. |
Industry | Healthcare |
